Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
News ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
